NewsSTAT
Ranked by formulaVerdict: RoutineSTAT+: Verastem's KRAS inhibitor shows promise in pancreatic cancer
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it's studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…
Score█████░░░░░5.2
Caveats
- Not randomized: its findings are associations.
VerdictCompetent work. Briefs at most.
Summary from the source
Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarcinoma and non-small…
The editor's rubric
| Dimension | Level | Weight | What that level means |
|---|---|---|---|
| Leverage | ██░░░ 2 | 15% | Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt). |
| Magnitude | ██░░░ 2 | 20% | Solid incremental gain on a meaningful problem. |
| Evidence | ███░░ 3 | 20% | Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data. |
| Novelty | ██░░░ 2 | 10% | A new combination of known ideas. |
| Trajectory | ██░░░ 2 | 10% | Some room to improve with obvious engineering. |
| Stakes | ██░░░ 2 | 25% | Benefits a professional community (practitioners, clinicians, engineers). |
Editor’s rationale
Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars); stakes (major disease). Red flags: not randomized.
How the score was computed
Score█████░░░░░5.2
- Merit
- 4.4 / 10
- Adjusted merit
- 4.1 / 10
- Attention
- 28%
- Freshness
- 99%